TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15016559
Drug: Timolol gel-forming
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol gel-forming ophthalmic solution 0.5% QD (n=39)
Study: 12516489
Drug: Diclofenac 1
Normalized name: diclofenac 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1 mg/Kg i.m. 60 minutes before surgery and continuous infusion of 1.5 mg/Kg over 24 hours (DD)
Study: 12516489
Drug: Diclofenac 1
Normalized name: diclofenac 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1 mg/Kg i.m. 60 minutes before surgery and infused saline solution after extubation (DP)
Study: 9690730
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O20AC500)
Study: 9690730
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 1000 mg b.d. (O20AC1000)
Study: 9690730
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O40AC500)
Study: 9690730
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 1000 mg b.d. (O40AC1000)
Study: 7864315
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of alfentanil (1 mg followed by 0.2 mg.h-1 infusion)
Study: 7864315
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of alfentanil
Study: 1081905
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with 1 chemotherapy agent
Study: 1081905
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with 2 chemotherapy agents
Study: 1081905
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with 3 chemotherapy agents
Study: 1081905
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with 4 chemotherapy agents
Study: 1081905
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with 3 drugs plus supplemental chemotherapy or irradiation (special categories)
Study: 29423663
Drug: Placebo formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulations spiked with silicone oil
Study: 29423663
Drug: Protein formulations
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein formulations stressed via freeze-thaw cycling, thermal incubation, and acid treatment
Study: 24482301
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks
Study: 22677045
Drug: Subcutaneous ixekizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ixekizumab (5, 15, 50, or 150 mg)
Study: 22677045
Drug: Subcutaneous ixekizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ixekizumab
Study: 16364049
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg intravenously infused over 10, 15, 20, or 30 minutes
Study: 16364049
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg intravenously as an injection over 3 minutes
Study: 9598622
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g co-amoxiclav intravenously followed by three further doses of oral co-amoxiclav (Group 1)
Study: 9598622
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g co-amoxiclav intravenously (Group 2)
Study: 7712689
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training in combination with selected resistance exercises (n = 17)
Study: 2472988
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of pirenzepine (PZ) intravenously every 12 hours
Study: 2472988
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of pirenzepine (PZ) intravenously every 12 hours
Study: 309031
Drug: Cold cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold cardioplegic method (Group A) - 4 degrees C. asanguineous solution with 30 mEq. of potassium per liter infused into the aortic root for about 2 minutes after aortic cross-clamping and again after 45 minutes or when myocardial temperature rose above 19 degrees C.
Study: 25842727
Drug: Intervention and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention and oral administration of Chinese medicine (Group A)
Study: 25842727
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Chinese medicine only (Group C)
Study: 23926681
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone undecanoate capsules combined with tadalafil
Study: 18447212
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus Fluoxetine
Study: 9821903
Drug: High-dose laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose laser therapy (5J/cm2)
Study: 9821903
Drug: Low-dose laser
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose laser therapy (0.5J/cm2)
Study: 9821903
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy (0J/cm2)
Study: 8179848
Drug: Nebivolol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (1, 5, or 10 mg)
Study: 8021909
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (12.5 mg)
Study: 8021909
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (25 mg)
Study: 8021909
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebivolol and HCTZ
Study: 31376435
Drug: Topical Thrombin
Normalized name: thrombin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Thrombin (Human) Grifols (TTH-Grifols)
Study: 28669689
Drug: rHuEPO (epoetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (epoetin β; mean dose 6000 IU per week)
Study: 23439901
Drug: SBME mastery
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBME mastery learning for child intravenous line placement (CIV)
Study: 21739598
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral antioxidant supplementation (900 IU of alpha‐tocopherol, 200 mg of ascorbic acid, and 600 mg of alpha‐lipoic acid)
Study: 19545481
Drug: Group-based mindfulness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based mindfulness training (twice-weekly sessions for 5 weeks, plus home practice)
Study: 16481635
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Study: 15318466
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg(‐1) intravenously
Study: 8282920
Drug: Erection enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erection enhancement pill
Study: 8282920
Drug: Erection detraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erection detraction pill
Study: 29929437
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - participated in six group sessions with an active peer model, received exercise prescription and PA information
Study: 24694983
Drug: Colchicine (0·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0·5 mg twice daily for patients >70 kg or 0·5 mg once daily for patients ≤70 kg)
Study: 22541841
Drug: Oral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naloxone 5 mg
Study: 22541841
Drug: Oral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naloxone 20 mg
Study: 22541841
Drug: Oral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naloxone 40 mg
Study: 22541841
Drug: Oral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naloxone 80 mg
Study: 22541841
Drug: Oral naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naloxone 120 mg
Study: 22541841
Drug: Rectal naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal naloxone (dose not specified)
Study: 19935757
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract tablets
Study: 16019862
Drug: Local hyperthermia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local hyperthermia treatment (30-min sessions twice a week for 5 weeks, total of 20 sessions at 39-40 degrees C)
Study: 16019862
Drug: Intra-plaque infiltrations
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-plaque infiltrations using 10 mg verapamil (one infiltration once a week for 3 months)
Study: 10807619
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 500 microgram twice daily
Study: 1640130
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of midazolam
Study: 1640130
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection followed by continuous infusion of midazolam
Study: 6696291
Drug: Inhaled diphemanil
Normalized name: Diphemanil
DrugBank: Diphemanil (DB13720)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled diphemanil (2 mg)
Study: 27876353
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cell (MNC) injections intradermally
Study: 27876353
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections intradermally
Study: 22481421
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin (50,000 units/kg OD IM) and gentamicin (5 mg/kg OD IM)
Study: 22481421
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 mg/kg OD IM)
Study: 22481421
Drug: Oral trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim-sulfamethoxazole (TMP-SMX) at 10 mg/kg/day divided twice daily and gentamicin IM OD
Study: 19917596
Drug: Trauma-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused treatment
Study: 19917596
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education group treatment
Study: 18401254
Drug: Sedatives and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedatives and opioids
Study: 29243546
Drug: Sedatives
Normalized name: SEDATIVES/HYPONTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedatives
Study: 10475317
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus fentanyl (100 microg) with 1.5% lidocaine and epinephrine test dose
Study: 10475317
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 1.5% lidocaine and epinephrine test dose
Study: 10475317
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control group (3 mL isotonic sodium chloride solution)
Study: 10475317
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (propofol and propofol-fentanyl) with test dose
Study: 7815584
Drug: 15% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% and 20% papaverine base gel applied to the scrotum, perineum, and penis
Study: 7815584
Drug: 15% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% and 20% papaverine base gel
Study: 1941852
Drug: Intralesional interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional interferon alpha-2b (1.5 million units, nine injections)
Study: 7023494
Drug: Fluproquazone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone (100 mg)
Study: 30589790
Drug: Acetyl-L-Carnitine 3000
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-Carnitine 3000 mg/day for 2 months
Study: 25534726
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg nemonoxacin
Study: 25534726
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg nemonoxacin
Study: 25534726
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg nemonoxacin
Study: 21107298
Drug: SCE‐A vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCE‐A vaginal cream (1 g once daily for 7 days, then twice weekly for 27 days)
Study: 21107298
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg SCE‐A oral tablets (once daily for 27 days)
Study: 19365317
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (proton pump inhibitors)
Study: 17065847
Drug: Valacyclovir 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1.0 g daily for 6 months
Study: 14742366
Drug: i.v. parecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. parecoxib 40 mg followed by oral valdecoxib 40 mg
Study: 10467840
Drug: Serum ADA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ADA level > or = 53.76 U/l
Study: 2079774
Drug: Alcohol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (mean blood alcohol level approximately 69.5 mg%; SE 6.20 mg%)
Study: 30770519
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg at weeks 0, 4, 12, and 20
Study: 26433431
Drug: Daptomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (4 mg/kg once)
Study: 26433431
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg every 12 h)
Study: 9602597
Drug: No volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: No volatile agent
Study: 19175400
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 10 mg/kg twice daily (b.i.d.)
Study: 19175400
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 20 mg/kg twice daily (b.i.d.)
Study: 12556405
Drug: Enalapril (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (angiotensin converting enzyme inhibitor)
Study: 2121911
Drug: 18 or
Normalized name: Panlor Reformulated Jan 2018 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 or 24 Gy radiation therapy (RT) to gonads (group 1)
Study: 31682027
Drug: Granular slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular slow-release enteric-coated PAS 4 g twice daily
Study: 31682027
Drug: Granular slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular slow-release enteric-coated PAS 8 g once daily
Study: 28430910
Drug: Pitavastatin plus
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin plus ezetimibe (intensive LDL-C lowering, target LDL-C < 70 mg/dL)
Study: 28430910
Drug: Pitavastatin monotherapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin monotherapy (standard LDL-C lowering, target LDL-C 90-100 mg/dL)
Study: 28430910
Drug: Pitavastatin plus
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin plus ezetimibe (in patients with higher cholesterol absorption)
Study: 19111995
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality relaxation plus intravenous morphine PCA infusion
Study: 19111995
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine PCA infusion alone
Study: 15297305
Drug: Multiple intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple intervention including group education meetings, consensus procedure on antibiotic indication and type, communication skills training, monitoring and feedback on prescribing behaviour, education for assistants and pharmacists, and educational material for patients.
Study: 11890487
Drug: Haloperidol 1
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1 to 5 mg/day
Study: 11890487
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 to 250 mg/day
Study: 9673476
Drug: Polyacrylic acid
Normalized name: polyacrylic acid sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyacrylic acid 0.2% (PAA) gel
Study: 7989638
Drug: Three-phase sequential
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-phase sequential treatment strategy
Study: 28121041
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic prophylaxis (intravenous cefuroxime 750 mg plus metronidazole 500 mg, three times daily for 3 days after surgery)
Study: 28121041
Drug: Standard prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis (single preoperative dose of cefazolin 2000 mg)
Study: 28121041
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic prophylaxis
Study: 8845664
Drug: Transfer Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer Factor (TF), administered subcutaneously daily for 3 to 4 days during the acute phase, followed by maintenance dosages at 15-day intervals for the first 6 months and monthly thereafter.
Study: 2667687
Drug: Heater probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heater probe therapy (n = 20)
Study: 29741923
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 23)
Study: 29153730
Drug: Intranasal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketorolac (31.5 mg) with nitrous oxide/oxygen
Study: 29153730
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline placebo with nitrous oxide/oxygen
Study: 20889877
Drug: Iron (2
Normalized name: prenatal#50/iron fum,bisgly/FA 25 mg iron (23 mg-2 mg)-1 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (2 mg/kg/day) plus folate (5 mg/day)
Study: 17332786
Drug: Regular physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular physical activity (e.g., brisk walking for at least 30 min daily)
Study: 24226492
Drug: Morphine (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (standardized dose 30 minutes before the end of surgery)
Study: 21279704
Drug: NACT +
Normalized name: Nacton
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACT + radiotherapy (RT) + adjuvant chemotherapy (AC)
Study: 19416133
Drug: Lansoprazole maintenance
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole maintenance therapy for up to 82 months
Study: 17522560
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole 10-15 mg/day (n = 153)
Study: 17522560
Drug: Oral haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral haloperidol 7.5-10 mg/day (n = 151)
Study: 15374803
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine therapy
Study: 29773326
Drug: Tremelimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses
Study: 10472344
Drug: Amifostine as
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine as a bolus injection (200 mg/m2 dissolved in 10 ml sodium chloride 0.9%)
Study: 10472344
Drug: Amifostine as
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine as a bolus injection
Study: 8709324
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg urapidil for 4 weeks (group 2)
Study: 8709324
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg urapidil for 2 weeks followed by 60 mg for 2 weeks (group 3)
Study: 1876628
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 micrograms/kg, single i.v. dose)
Study: 6283753
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg penbutolol (pure S‐form)